Search research articles
Contact Us
Filters
Showing results (321-330 of 387) with videos related to
Page
of 39
Sort By:
Journal of Hepatology
|
October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Stefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Gastroenterologia Y Hepatologia
|
February 2, 2023
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)
Mar Riveiro-Barciela, Luisa Roade, Joan Martínez-Camprecios, et al.
The American Journal of Gastroenterology
|
August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
Henry L Y Chan, Maria Buti, Young-Suk Lim, et al.
Hepatology (Baltimore, Md.)
|
June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
George V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
Journal of Hepatology
|
January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
George V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.
Journal of Hepatology
|
February 11, 2018
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
George V Papatheodoridis, Vana Sypsa, George Dalekos, et al.
The Lancet. Infectious Diseases
|
February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns, Didier Samuel, Edward J Gane, et al.
Journal of Hepatology
|
August 27, 2023
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
Aleksander Krag, Maria Buti, Jeffrey V Lazarus, et al.
Alimentary Pharmacology & Therapeutics
|
September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Maria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.
Page
of 39
Search research articles
Search
Showing results (321-330 of 387) with videos related to
Sort By:
Page
of 39
Journal of Hepatology
|
October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Stefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Gastroenterologia Y Hepatologia
|
February 2, 2023
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)
Mar Riveiro-Barciela, Luisa Roade, Joan Martínez-Camprecios, et al.
The American Journal of Gastroenterology
|
August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
Henry L Y Chan, Maria Buti, Young-Suk Lim, et al.
Hepatology (Baltimore, Md.)
|
June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
George V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
Journal of Hepatology
|
January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
George V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.
Journal of Hepatology
|
February 11, 2018
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
George V Papatheodoridis, Vana Sypsa, George Dalekos, et al.
The Lancet. Infectious Diseases
|
February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns, Didier Samuel, Edward J Gane, et al.
Journal of Hepatology
|
August 27, 2023
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
Aleksander Krag, Maria Buti, Jeffrey V Lazarus, et al.
Alimentary Pharmacology & Therapeutics
|
September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Maria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.
Page
of 39